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INTRODUCTION
Leptomeningeal gliomatosis is a condition characterized by 
widespread extension into the leptomeninges and seeding in 
the subarachnoid space of glial tumor cells. Most cases of lep-
tomeningeal gliomatosis are the secondary spreads of neoplas-
tic glial cells from primary intraparenchymal glioma, which 
usually occur late in the development of malignant glioma. Pri-
mary diffuse leptomeningeal gliomatosis (PDLG), which aris-
es primarily in the leptomeninges without evidence of a pri-
mary parenchymal tumor of the central nervous system (CNS), 
is a very rare presentation of a glial tumor, with less than 90 pa-
tients reported to date [1]. It is a very aggressive and fatal dis-
ease with various grades of histopathology including glioblas-
toma, anaplastic astrocytoma, anaplastic oligoastrocytoma, 
anaplastic oligodendroglioma, oligodendroglioma, ependy-
moblastoma, primitive neuroectodermal tumor, and low-grade 
astrocytoma [2]. Among the reported patients with PDLG, there 
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Primary diffuse leptomeningeal gliomatosis (PDLG) is a rare condition with a fatal outcome, character-
ized by diffuse infiltration of the leptomeninges by neoplastic glial cells without evidence of primary tu-
mor in the brain or spinal cord parenchyma. In particular, PDLG histologically diagnosed as gliosarcoma 
is extremely rare, with only 2 cases reported to date. We report a case of primary diffuse leptomeningeal 
gliosarcomatosis. A 68-year-old man presented with fever, chilling, headache, and a brief episode of 
mental deterioration. Initial T1-weighted post-contrast brain magnetic resonance imaging (MRI) showed 
diffuse leptomeningeal enhancement without a definite intraparenchymal lesion. Based on clinical and 
imaging findings, antiviral treatment was initiated. Despite the treatment, the patient’s neurologic symp-
toms and mental status progressively deteriorated and follow-up MRI showed rapid progression of the 
disease. A meningeal biopsy revealed gliosarcoma and was conclusive for the diagnosis of primary dif-
fuse leptomeningeal gliosarcomatosis. We suggest the inclusion of PDLG in the potential differential di-
agnosis of patients who present with nonspecific neurologic symptoms in the presence of leptomenin-
geal involvement on MRI.
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are only two cases diagnosed histopathologically as gliosarco-
ma [3,4]. Gliosarcoma is a rare primary malignant CNS neo-
plasm composed of an admixture of gliomatous and sarcoma-
tous components, accounting for approximately 2% of all cases 
of glioblastoma [5]. It is an aggressive neoplasm with poor 
prognosis, classified as Grade IV neoplasm in the World Health 
Organization classification scheme. We present an extremely 
rare case of PDLG histopathologically diagnosed as gliosarco-
ma, which can be referred to as primary diffuse leptomenin-
geal gliosarcomatosis.
CASE REPORT
A 68-year-old man with an untreated pituitary mass was re-
ferred to the department of neurology due to fever, chilling, 
headache, and a brief episode of mental deterioration. Neuro-
logic examination at the first presentation was normal. T1-
weighted post-contrast brain magnetic resonance imaging 
(MRI) showed diffuse leptomeningeal enhancement promi-
nently along the right frontal, right operculum, right tempo-
ral, left cerebellum, left ambient cistern, interpeduncular cis-
tern, bilateral sylvian fissure, and cervicomedullary junction 
without any massive intra-axial involvement (Fig. 1). On this 
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MRI, there is no interval change of the pituitary lesion com-
pared to the MRI taken two years prior. 
Cerebrospinal fluid (CSF) analysis revealed a normal open-
ing pressure of 80 mm H2O, one white blood cell/mm3, a slightly 
elevated protein level of 50.5 mg/dL, a normal glucose level, 
and adenosine deaminase activity of 1.6 U/L. Based on clinical 
and imaging findings, a diagnosis of probable viral meningo-
encephalitis was made by a neurologist, and antiviral drug treat-
ment (acyclovir 1,500 mg/day) and steroid treatment (dexa-
methasone 20 mg/day) were started.
Cultures and serology of serum and CSF were negative for 
bacteria, virus, fungi, and Mycobacterium tuberculosis. Poly-
merase chain reaction (PCR) for herpes simplex virus type 1 
and type 2 was negative. Extensive laboratory evaluations for 
infectious and inflammatory causes of meningitis were neg-
ative. Cytologic examination of CSF was not performed.
After two weeks of treatment with acyclovir and dexameth-
asone, the patient’s symptoms including fever and headache 
improved, and he exhibited a more alert mentality. However, 
unlike the improvement in clinical symptoms, the follow-up 
brain MRI taken one month after the completion of antiviral 
treatment showed no definite interval change in the extent of 
enhancing lesions. Since tumorous conditions including lym-
phoma, leptomeningeal carcinomatosis, and leptomeningeal 
gliomatosis were suspected based on the MRI findings, whole-
body positron emission tomography-computed tomography 
(PET-CT) was performed. A whole-body PET-CT showed in-
tense fluorodeoxyglucose uptake in the leptomeningeal en-
hancing lesions on MRI without other significant increased up-
take in the whole body area except the pituitary gland (Fig. 2). 
A biopsy of the leptomeningeal lesions for pathologic diagno-
sis was recommended due to the malignancy indications of these 
findings, but the patient and his family refused biopsy and did 
not attend follow-up examinations.
Three months later, he revisited our emergency room with 
intractable headache, diplopia, confusion, and progressive de-
terioration of mental status. Further MRI of the brain showed 
rapid disease progression with expansion of leptomeningeal 
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Fig. 1. Axial (A) and sagittal (B) T1-weighted post-contrast magnetic resonance imaging showed diffuse leptomeningeal enhancement promi-
nently along the right frontal, right operculum, right temporal, left cerebellum, left ambient cistern, interpeducluar cistern, bilateral sylvian fis-
sure, and cervicomedullary junction without any massive intraaxial involvement.
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Fig. 2. Axial image (A) of the whole-body positron emission tomog-
raphy-computed tomography (PET-CT) showed intense fluorode-
oxyglucose (FDG) uptake in the leptomeningeal enhancing lesions 
on magnetic resonance imaging (arrows). Coronal image (B) of the 
PET-CT showed linear increased FDG uptake throughout the cer-
vical and upper thoracic spinal cords (arrows). These findings were 
suggestive of leptomeningeal involvement of malignancy.
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enhancement throughout the brain, multiple cranial nerve in-
filtration of lesions, and exacerbation of parenchymal edema 
adjacent to the leptomeningeal enhancing lesions (Fig. 3). 
Open surgical biopsy of the temporal leptomeningeal lesion 
was performed via right frontotemporal craniotomy. The in-
traoperative findings revealed a pinkish tumor mass with high 
vascularity that firmly adhered to the dura mater and was easi-
ly separated from the brain cortex. Histopathologic examina-
tion revealed a highly proliferative tumor with markedly in-
creased nuclear Ki-67 staining that had a biphasic component 
of glial and sarcomatous cells. In the glial component, there 
were microvascular proliferations and areas of necrosis, and 
the number of mitotic figures per 10 high-power fields was 5– 
6, and the Ki-67 labeling index at the hot spot was 20%. The 
glial component showed hyperchromatic features with high 
cell density and stained positive using antibodies against glial 
markers including glial fibrillary acidic protein and oligoden-
drocyte lineage transcription factor 2. In the sarcomatous com-
ponent, the number of mitotic figures per 10 high-power fields 
was 2–3, and the Ki-67 labeling index at the hot spot was 10%. 
The sarcomatous component, which is composed of interweav-
ing fascicles of spindle cells, was negative for glial marker, yet 
positive for reticulin and trichrome, showing surrounding 
abundant reticular fibers and collagens. Therefore, the patho-
logical diagnosis of gliosarcoma was established (Fig. 4). Im-
munohistochemical analysis showed wild-type isocitrate de-
hydrogenase 1, and it was confirmed by direct sequencing. Me-
thylation-specific PCR showed O-6-methylguanine methyltrans-
ferase promoter methylation. Intact 1p and 19q were detected 
by fluorescence in situ hybridization. p53 showed nuclear posi-
tivity in almost 20% of tumor cells.
We planned whole-brain radiotherapy with concurrent ad-
ministration of temozolomide for the patient postoperatively. 
While preparing for the adjuvant treatment, the patient’s con-
dition deteriorated rapidly to stuporous mental status despite 
mannitolization and steroid therapy for controlling the intra-
cranial pressure. The patient’s family strongly forbade adjuvant 
treatment, and the patient was transferred to a local hospital 
for palliative care. He expired soon after, five months after ini-
tial presentation; an autopsy was not performed.
DISCUSSION
Primary leptomeningeal glioma is a rare condition with un-
clear etiology. Two major anatomical and clinical forms of pri-
mary leptomeningeal glioma have been described: a solitary 
form and a diffuse form. A solitary form has been described as 
a limited solitary mass in cranial or spinal leptomeninges that 
mimics an extra-axial CNS tumor. We presented a case of sol-
itary primary leptomeningeal glioma in our previous report [6]. 
A diffuse form described as a diffuse extension of glial tumor 
cells over a wide area of the CNS without intra-axial mass con-
stitutes the majority of primary leptomeningeal glioma, and 
has a more dismal prognosis than the solitary form [7]. In the 
present report, we described a rapidly progressive case of PDLG 
histologically diagnosed as gliosarcoma with fatal outcome.
The diagnosis of PDLG should satisfy the three following cri-
teria [8]: 1) no apparent attachment of extramedullary menin-
geal tumor to the neural parenchyma, 2) no evidence of pri-
mary neoplasia within the neuraxis, and 3) the existence of 
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Fig. 3. Axial (A) and sagittal (B) T1-weighted post-contrast magnetic resonance imaging showed rapid disease progression with expansion of 
leptomeningeal enhancement throughout the brain, multiple cranial nerve infiltration of lesions, and exacerbation of parenchymal edema ad-
jacent to the leptomeningeal enhancing lesions.
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distinct leptomeningeal encapsulation around the tumor. Pri-
or to the advance of high-resolution imaging, the definitive di-
agnosis of PDLG, thus, required autopsy to rule out a primary 
parenchymal source of the leptomeningeal spread. The devel-
opment of gadolinium-enhanced MRI has significantly in-
creased the ability to diagnose PDLG. Our case successfully 
satisfied the three criteria for diagnosis of PDLG. 
Nevertheless, our case highlights the difficulty in diagnosing 
PDLG. The clinical presentation, CSF findings, and neuroim-
aging results observed in PDLG are nonspecific. Clinical pre-
sentations of PDLG usually appear to develop in two stages. 
The prodromal phase consisted of various signs of subacute 
meningitis or encephalomyelitis, and a second phase consists 
of nonspecific neurological impairment, which could mimic 
numerous neurological diseases [2,7]. There are various signs 
and symptoms that PDLG may manifest, including headache, 
nausea, vomiting, meningismus, cranial nerve palsy, seizure, 
and mental state alteration [2]. CSF examination in patients di-
agnosed with PDLG usually reveals high protein levels, nor-
mal or minimally decreased glucose concentrations, and low 
or moderate pleocytosis [9]. However, the result of CSF exami-
nation of PDLG varies from case to case. Unlike in secondary 
meningeal gliomatosis or leptomeningeal carcinomatosis, the 
identification of malignant cells via CSF cytologic examination 
is very rare in PDLG [10]. Because of these symptomatic fea-
tures and equivocal results of CSF examination, infectious, in-
flammatory, granulomatous, and neoplastic conditions were 
all considered at various stages of the clinical course. It is com-
mon for PDLG to be initially considered an infectious condi-
tion and to be mistreated with antituberculous, antiviral, or an-
tifungal therapy, because the clinical and CSF findings resemble 
those of chronic infectious meningitis. Our patient initially pre-
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Fig. 4. Photomicrographs. A: Hematoxylin and eosin (H&E) stain of the astrocytic component of the tumor (×400) is shown. B: A portion of 
the tumor demonstrated sarcomatous, spindle morphology (H&E stain, ×400). C: Microvascular proliferation (arrows) was observed through-
out the glial component (H&E stain, ×400). D: Presence of areas of pseudopalisading necrosis (arrows) in the glial component (H&E stain, 
×100). E and F: Focal glial fibrillary acidic protein (GFAP) and oligodendrocyte lineage transcription factor 2 (OLIG2) staining (×100) is evi-
dent in the astrocytic portion of the gliosarcoma (arrows). By contrast, the sarcomatous portion is negative for GFAP and OLIG2. G and H: The 
sarcomatous component is rich in trichrome (G) and reticulin (H) (×200).
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sented with symptoms of meningoencephalitis such as fever, 
chilling, and headache, and the MRI showed diffuse leptomen-
ingeal enhancement, which can be observed in infectious con-
ditions. In addition, CSF analysis in our patient was not com-
patible with bacterial or tuberculous meningitis. Based on these 
clinical and imaging findings, the patient was initially misdiag-
nosed with viral meningoencephalitis and treated with antivi-
ral agents and steroids. There was an ephemeral improvement 
in the patient’s symptoms, but the patient worsened both clin-
ically and radiologically.
To our knowledge, this is the third reported case of PDLG 
histologically diagnosed as gliosarcoma. As the first [3] and 
second [4] reports of primary diffuse leptomeningeal gliosar-
comatosis, diffuse meningeal involvement at the time of pre-
sentation without parenchymal lesion in our case supports the 
fact that the gliomatous and sarcomatous components of glio-
sarcoma are derived from a monoclonal origin, and PDLG aris-
es from nests of heterotopic glial tissue. In addition, our case il-
lustrates the fatal and rapidly progressive nature of the untreated 
disease with severe aggravation of the clinical condition and 
serial MRI of the patient.
When diffuse leptomeningeal enhancement is evident on 
the MRI of the neuraxis, diagnosis can be very challenging. We 
suggest the inclusion of PDLG in the potential differential di-
agnosis of patients who present with nonspecific neurologic 
symptoms in the presence of leptomeningeal involvement on 
MRI. Early meningeal biopsy is strongly recommended in pa-
tients who fail to respond to first-line treatments for infectious 
conditions with worsening neurological symptoms.
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